GSK topped the list, thanks to its June 2021 deal with iTeos for an anti-TIGIT called EOS-448 that totaled more than $2 billion in potential value—over $600 million of which came in upfront cash.

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a meaningful benefit in two Phase II trials. Belrestotug, a human IgG1 antibody ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

GlaxoSmithKline has staked a claim to the fast-moving category of cancer therapies targeting the TIGIT immune checkpoint, agreeing a $2 billion plus licensing agreement with iTeos Therapeutics for ...

GSK has stopped development of anti-TIGIT antibody belrestotug. The Big Pharma and its partner iTeos Therapeutics took the action after an assessment of the effect on progression-free survival ...

iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a key trial for Roche's rival ...

GlaxoSmithKline has agreed to buy an anti-TIGIT antibody for cancer immunotherapy from iTeos Therapeutics for $625 million upfront and up to $1.45 billion in milestone payments.

A targeted immunotherapy being developed by iTeos Therapeutics and GSK, it was reported at #ESMO, delivered promising response rates in patients with a type of lung cancer.

Iteos Therapeutics said it has sold ownership rights to an experimental anti-TIGIT cancer antibody to GlaxoSmithKline — the most recent deal for a drug in the unproven, but highly sought-after ...

GlaxoSmithKline is paying iTeos Therapeutics $625 million up front to share in the development of an antibody that targets the TIGIT protein, a hot target in cancer immunotherapy R&D. The deal ...

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a meaningful benefit in two Phase II trials.